AstraZeneca Wins EU Approval for Enhertu Combination in First-Line Breast Cancer
AstraZeneca and Daiichi Sankyo said Enhertu plus pertuzumab was approved in the EU as first-line treatment for adults with unresectable or metastatic HER2-positive…
Novartis Says Remibrutinib Cut MS Relapses Versus Teriflunomide in Phase 3 Trials
Novartis said two Phase 3 REMODEL trials of remibrutinib met their primary endpoint, reducing the annualized relapse rate versus teriflunomide in relapsing multiple…
UCB to Present 18 Epilepsy Abstracts at European Congress in Athens
UCB said it will present 18 abstracts at the 16th European Epilepsy Congress in Athens from Sept. 5 to Sept. 9. A post…
Qiagen Launches Automated Clinical Nucleic Acid Extraction Platform
Qiagen N.V. commercially launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. The new system aims to standardize extraction across…
Lonza Names Samanta Cimitan Chief Commercial Officer
Lonza appointed Samanta Cimitan as Chief Commercial Officer, the company said. Cimitan will join Lonza by January 1, 2027, in the newly created…
QIAGEN Appoints Jonathan Pratt as Chief Executive Officer
QIAGEN appointed Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of leadership experience…
Fresenius To Sell €300 Million in Medical Care Shares
Fresenius agreed to sell approximately 7.8 million Fresenius Medical Care shares, equivalent to about 2.9% of the company’s issued share capital. The transaction…
Novartis to Showcase Cardiovascular Data at ESC Congress
Novartis plans to present 10 abstracts on its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress. Late-breaking Phase 4 VICTORION-CHALLENGE…
AstraZeneca Stops Phase III Lung Cancer Trial for Volrustomig
London, U.K. — AstraZeneca announced on August 17, 2026, the discontinuation of its eVOLVE-Lung02 Phase III trial. The trial evaluated volrustomig in combination…
UPDATE: UCB’s Bimzelx Shows Sustained Efficacy in Three-Year Skin Disease Study
• 40.1% of patients achieved total resolution of inflammatory lesions at year three. • Patients with severe hidradenitis suppurativa dropped from 87.4% at…